<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042271</url>
  </required_header>
  <id_info>
    <org_study_id>meropenem-plasma exchange</org_study_id>
    <nct_id>NCT05042271</nct_id>
  </id_info>
  <brief_title>PK of Meropenem in Patients on Plasma Exchange</brief_title>
  <official_title>Pharmacokinetics of Meropenem in Patients on Plasma Exchange</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic plasma exchange (TPE) has been shown to be an important procedure for treatment&#xD;
      of a variety of refractory immune complex disorders, such as Guillain-Barré syndrome and&#xD;
      neuromyelitis optica. The intervention removes plasma, albumin, or some other substance.&#xD;
      Meropenem is a broad-spectrum beta-lactam antimicrobial agent that is used for the treatment&#xD;
      of serious nosocomial infections. Pathophysiological changes in patients on TPE can alter the&#xD;
      pharmacokinetic (PK) patterns of coadministered antibiotics. This effect has an impact on the&#xD;
      antimicrobial agents when paticipants are administered during the intervention. The aim of&#xD;
      this study was to investigate the impact of TPE on meropenem PK.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The plasma concentrations were measured at the following times: 0, 0.25, 0.5, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hour after the start of drug administration</measure>
    <time_frame>0-8 hours after the drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>0-8 hours after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration [Cmin]</measure>
    <time_frame>0-8 hours after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve [AUC]</measure>
    <time_frame>0-8 hours after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life [t1/2]</measure>
    <time_frame>0-8 hours after the drug administration</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Meropenem: Patients who underwent TPE (Phase 1)</arm_group_label>
    <description>In phase 1, each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first therapeutic plasma exchange (TPE) and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem: after TPE (Phase 2)</arm_group_label>
    <description>was similar to phase 1 except that the meropenem administration and PK studies were conducted &gt;6 hours apart from the next TPE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem</intervention_name>
    <description>each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.</description>
    <arm_group_label>Meropenem: Patients who underwent TPE (Phase 1)</arm_group_label>
    <arm_group_label>Meropenem: after TPE (Phase 2)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        autoimmune diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age≥ 18 years&#xD;
&#xD;
          -  no shock&#xD;
&#xD;
          -  hemoglobin ≥ 7 g/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breast-feeding female&#xD;
&#xD;
          -  history of hypersensitivity to carbapenems&#xD;
&#xD;
          -  renal replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Prince of Songkla University, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
    <phone>66741485</phone>
    <email>jasutep@medicine.psu.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>monchana Nawakitrangsan, M.Pharm</last_name>
    <phone>66741585</phone>
    <email>nana_jittung@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Prince of Songkla University, Thailand</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
      <phone>6674-451485</phone>
      <email>jasutep@medicine.psu.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Monchana Nawakitrangsan, M.Pharm</last_name>
      <phone>6674-451486</phone>
      <email>nana_jittung@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Sutep Jaruratanasirikul</investigator_full_name>
    <investigator_title>Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University</investigator_title>
  </responsible_party>
  <keyword>therapeutic plasma exchange</keyword>
  <keyword>meropenem</keyword>
  <keyword>pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

